Adjunct Partners
Martin Zeiger
Adjunct Partner
New York, NY

Mr. Zeiger is an Adjunct Partner with Signet Healthcare Partners. He has more than 25 years experience in many aspects of management in the pharmaceutical industry, both branded and generic.

Mr. Zeiger is currently a Director of BioPro, Cedarburg Pharmaceuticals and the Larry King Cardiac Foundation.

Prior to joining Signet Healthcare Partners, Mr. Zeiger was a Senior Vice President at Barr Laboratories, Inc. Prior to joining Barr, Mr. Zeiger was Executive Vice President and General Counsel at Rugby Laboratories (a privately held generic drug company) until its acquisition by Marion Merrill Dow, Inc. in 1993. He continued as a Vice President for Marion and its successor Company, Hoechst Marion Roussel, Inc.

Mr. Zeiger was honored by Generic Pharmaceutical Industry Association at its March 2004 Annual Meeting as a generic industry founder. Prior to joining pharmaceutical manufacturing companies, Mr. Zeiger served as Vice President General Counsel for Jack Eckerd Corporation and Senior Vice President for Revco D.S. Inc. both major drug store retailers.

Mr. Zeiger is an attorney, admitted to practice in the State of New York.

He received his LLB and JD from St.John’s University School of Law, where he served as Publications Editor of the Law Review.

Samuel Altman
Adjunct Partner
New York, NY

Mr. Altman is an Adjunct Partner with Signet Healthcare Partners. Prior to joining Signet Healthcare Partners, Mr. Altman was President and Chief Executive Officer of Pendopharm Inc., a Montreal-based OTC and Pharmaceutical contract manufacturer, and was an Independent Consultant where he served and advised healthcare, and industrial marketing clients on strategy, corporate development and M&A. Mr. Altman led corporate strategy and investment for a $1 billion revenue publicly-listed holding company as Senior Vice President, Corporate Development, at Scott’s Hospitality Inc. As a Management Consultant, at McKinsey and Company, he advised industrial and retail marketing clients across North America, Mexico and Europe. He is also the President of Joddes Limited, a Canadian-based investment company with major positions in several healthcare companies.

Mr. Altman received his J.D. (law) from Queen’s University, Kingston, Canada and his MBA from Johnson Graduate School of Management at Cornell University. He is a CFA charter holder and is a member of the Law Society of Upper Canada.

David Tierney, MD
Venture Partner
New York, NY

David Tierney, MD is a Venture Partner with Signet Healthcare Partners, a NYC based life sciences private equity fund. Prior to joining Signet, David was most recently co-founder, President and Chief Operating Officer of Oceana Therapeutics, a specialty medical device company focused on urologic and GI disorders which was acquired by Salix Pharmaceuticals, Inc. in December 2011. From 2000 to 2007, David was President, CEO and Director of Valera Pharmaceuticals, where he implemented and executed a business plan successfully transitioning the company from a science-based polymer research organization into an integrated specialty pharmaceutical company. Under David’s leadership, Valera actively pursued and received a number of regulatory product approvals, completed an initial public offering in 2006 and was acquired in 2007 by Endo Pharmaceuticals. Prior to Valera, David served as President of Biovail Technologies (a division of Biovail Corp.). From 1997 through 1999, he held the position of Senior Vice President, Drug Development, for Roberts Pharmaceutical Corp. Before joining Roberts, David spent eight years at Elan Corp. in a variety of management positions. During his time at Elan, David was involved in the development of numerous successful new drug applications. David also serves on the Board of Directors of Catalyst Pharmaceutical Partners (CPRX:NASDAQ) and Bioject, Inc. David received his medical degree from the Royal College of Surgeons in Dublin, Ireland.